Citations 1
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. , Halvorson, Alese E. , Hoke, Eva , Godwin, John E. , Couban, Stephen, Fehniger, Todd A. , Thirman, Michael J. , Tallman, Martin S. , Appelbaum, Frederick R. , Stone, Richard M. , Robinson, Sue, Chang, Julie E., Mandrekar, Sumithra J. , Byrd, John C. , Fehniger, Todd A , Smith, Mitchell R. , Chang, Julie E., Larson, Richard A. , Byrd, John C
Blood Advances | July 20, 2018 | Volume: 2 | Issue: 14 | Pages: 1705-1718
10.1182/bloodadvances.2017015396
Key PointsBrief lenalidomide consolidation after chemoimmunotherapy is acceptably tolerated and extends PFS and OS in CLL. FCR has superior efficacy compared with FR chemoimmunotherapy for CLL.